ECSP13012495A - Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina - Google Patents
Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquininaInfo
- Publication number
- ECSP13012495A ECSP13012495A ECSP13012495A ECSP13012495A EC SP13012495 A ECSP13012495 A EC SP13012495A EC SP13012495 A ECSP13012495 A EC SP13012495A EC SP13012495 A ECSP13012495 A EC SP13012495A
- Authority
- EC
- Ecuador
- Prior art keywords
- tetrahydrofuranilo
- bradiquinine
- antagonists
- receiver
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Objeto de la presente invención son compuestos de tetrahidrofuranilo disustituidos de la Fórmula general I (I)en la que las variables R1, R2 y X se definen de la forma descrita a continuación, sus enantiómeros, sus diastereoisómeros, sus mezclas y sus sales, en especial sus sales fisiológicamente aceptables con ácidos o bases orgánicos o inorgánicos, que poseen propiedades valiosas, un procedimiento para su fabricación, los medicamentos que contienen los compuestos farmacológicamente efectivos, así como su fabricación y uso.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10173489 | 2010-08-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP13012495A true ECSP13012495A (es) | 2013-04-30 |
Family
ID=44510978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP13012495 ECSP13012495A (es) | 2010-08-20 | 2013-03-15 | Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US8937073B2 (es) |
| EP (1) | EP2606042B1 (es) |
| JP (1) | JP5727011B2 (es) |
| KR (1) | KR101822371B1 (es) |
| CN (1) | CN103068817B (es) |
| AP (1) | AP2012006630A0 (es) |
| AR (1) | AR082507A1 (es) |
| AU (1) | AU2011290727B2 (es) |
| BR (1) | BR112013003752A2 (es) |
| CA (1) | CA2807086A1 (es) |
| CL (1) | CL2013000310A1 (es) |
| CO (1) | CO6680689A2 (es) |
| CY (1) | CY1115933T1 (es) |
| DK (1) | DK2606042T3 (es) |
| EA (1) | EA022787B1 (es) |
| EC (1) | ECSP13012495A (es) |
| ES (1) | ES2525296T3 (es) |
| GE (1) | GEP20146196B (es) |
| HR (1) | HRP20141172T1 (es) |
| IL (1) | IL224039A (es) |
| MA (1) | MA34578B1 (es) |
| ME (1) | ME01899B (es) |
| MX (1) | MX352548B (es) |
| MY (1) | MY156233A (es) |
| NZ (1) | NZ607435A (es) |
| PE (1) | PE20130810A1 (es) |
| PH (1) | PH12013500330A1 (es) |
| PL (1) | PL2606042T3 (es) |
| PT (1) | PT2606042E (es) |
| RS (1) | RS53622B1 (es) |
| SG (1) | SG187835A1 (es) |
| SI (1) | SI2606042T1 (es) |
| TW (1) | TWI548632B (es) |
| UA (1) | UA108765C2 (es) |
| UY (1) | UY33565A (es) |
| WO (1) | WO2012022795A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007034620A1 (de) * | 2007-07-25 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue B1-Antagonisten |
| CA2697946C (en) | 2007-08-29 | 2016-06-28 | Boehringer Ingelheim International Gmbh | Bradykinin b1-antagonists |
| US8937073B2 (en) | 2010-08-20 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists |
| WO2016040554A1 (en) | 2014-09-10 | 2016-03-17 | Temple University-Of The Commonwealth System Of Higher Education | Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
| WO2016183150A1 (en) * | 2015-05-12 | 2016-11-17 | Temple University-Of The Commonwealth System Of Higher Education | Novel sigma-2 receptor binders and their method of use |
| WO2021198534A1 (en) | 2020-04-04 | 2021-10-07 | Oxurion NV | Plasma kallikrein inhibitors for use in the treatment of coronaviral disease |
| US11401303B2 (en) * | 2020-06-15 | 2022-08-02 | Taian City Qihang Biotechnology Co. | Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof |
| WO2023148016A1 (en) | 2022-02-04 | 2023-08-10 | Oxurion NV | Biomarker for plasma kallikrein inhibitor therapy response |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7091380B2 (en) * | 2002-02-08 | 2006-08-15 | Merck & Co., Inc. | N-biphenylmethyl aminocycloalkanecarboxamide derivatives |
| TWI259079B (en) | 2002-02-08 | 2006-08-01 | Merck & Co Inc | N-biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives |
| RU2005108667A (ru) | 2002-08-29 | 2005-08-27 | Мерк энд Ко., Инк. (US) | Производные n-биарилметиламиноциклоалканкарбоксамида |
| CN1832922A (zh) * | 2003-08-07 | 2006-09-13 | 默克公司 | 磺酰基取代的n－(联芳基甲基)氨基环丙烷甲酰胺类 |
| CA2534188A1 (en) * | 2003-08-07 | 2005-02-24 | Merck & Co., Inc. | Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides |
| US20070189865A1 (en) | 2004-03-02 | 2007-08-16 | Bock Mark G | Amino cyclopropane carboxamide derivatives as bradykinin antagonists |
| US20060173023A1 (en) | 2005-02-01 | 2006-08-03 | Wood Michael R | 2-(Bicyclo)alkylamino-derivatives as mediators of chronic pain and inflammation |
| US7998980B2 (en) * | 2006-09-15 | 2011-08-16 | Hydra Biosciences, Inc. | Compounds for modulating TRPV3 function |
| HUP0600809A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| DE102007034620A1 (de) | 2007-07-25 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue B1-Antagonisten |
| EP2025675A1 (de) | 2007-08-14 | 2009-02-18 | Boehringer Ingelheim International GmbH | Arylsulfonamide mit analgetischer Wirkung |
| CA2697946C (en) | 2007-08-29 | 2016-06-28 | Boehringer Ingelheim International Gmbh | Bradykinin b1-antagonists |
| AR068509A1 (es) * | 2007-09-19 | 2009-11-18 | Jerini Ag | Antagosnistas del receptor de bradiquinina b1 |
| WO2010057899A1 (de) | 2008-11-20 | 2010-05-27 | Boehringer Ingelheim International Gmbh | Cykloalkylaminocarbonylderivate als bradykinin-b1-rezeptor antagonisten |
| WO2010097374A1 (de) | 2009-02-26 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Verbindungen als bradykinin-b1-antagonisten |
| ME01526B (me) * | 2009-02-26 | 2014-04-20 | Boehringer Ingelheim Int | Jedinjenja kao b1 antagonisti bradikinina |
| CN102781916B (zh) | 2010-02-23 | 2014-06-25 | 贝林格尔.英格海姆国际有限公司 | 作为缓激肽b1拮抗剂的化合物 |
| AR082492A1 (es) | 2010-08-20 | 2012-12-12 | Allergan Inc | N-alquil-2-(1-(5-sustituido-2-(3-oxo-3-(trifluorometilsulfonamido)propil)bencil)pirrolidin-2-il)oxazol-4-carboxamida y su uso para preparar un medicamento util para tratar enfermedades o afecciones mediadas por receptor dp, fp, ep, ep, tp y/o ep |
| US8759537B2 (en) | 2010-08-20 | 2014-06-24 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
| US8937073B2 (en) | 2010-08-20 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists |
| US8901127B2 (en) | 2010-08-20 | 2014-12-02 | Boehringer Ingelheim International Gmbh | Pyridazin derivatives as antagonists of the bradykinin B1 receptor |
| US8586604B2 (en) | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
-
2011
- 2011-08-12 US US13/208,567 patent/US8937073B2/en active Active
- 2011-08-19 EP EP11748634.0A patent/EP2606042B1/de active Active
- 2011-08-19 DK DK11748634.0T patent/DK2606042T3/da active
- 2011-08-19 PE PE2013000265A patent/PE20130810A1/es not_active Application Discontinuation
- 2011-08-19 AP AP2012006630A patent/AP2012006630A0/xx unknown
- 2011-08-19 PT PT117486340T patent/PT2606042E/pt unknown
- 2011-08-19 CN CN201180039753.8A patent/CN103068817B/zh not_active Expired - Fee Related
- 2011-08-19 MX MX2013001965A patent/MX352548B/es active IP Right Grant
- 2011-08-19 SI SI201130320T patent/SI2606042T1/sl unknown
- 2011-08-19 GE GEAP201113031A patent/GEP20146196B/en unknown
- 2011-08-19 BR BR112013003752A patent/BR112013003752A2/pt not_active IP Right Cessation
- 2011-08-19 AR ARP110103036A patent/AR082507A1/es not_active Application Discontinuation
- 2011-08-19 PH PH1/2013/500330A patent/PH12013500330A1/en unknown
- 2011-08-19 ES ES11748634.0T patent/ES2525296T3/es active Active
- 2011-08-19 UY UY0001033565A patent/UY33565A/es not_active Application Discontinuation
- 2011-08-19 NZ NZ607435A patent/NZ607435A/en not_active IP Right Cessation
- 2011-08-19 TW TW100129857A patent/TWI548632B/zh active
- 2011-08-19 MY MYPI2013000537A patent/MY156233A/en unknown
- 2011-08-19 PL PL11748634T patent/PL2606042T3/pl unknown
- 2011-08-19 JP JP2013524457A patent/JP5727011B2/ja active Active
- 2011-08-19 RS RS20140551A patent/RS53622B1/sr unknown
- 2011-08-19 EA EA201201662A patent/EA022787B1/ru not_active IP Right Cessation
- 2011-08-19 SG SG2013010764A patent/SG187835A1/en unknown
- 2011-08-19 UA UAA201303313A patent/UA108765C2/uk unknown
- 2011-08-19 CA CA2807086A patent/CA2807086A1/en not_active Abandoned
- 2011-08-19 KR KR1020137004077A patent/KR101822371B1/ko not_active Expired - Fee Related
- 2011-08-19 MA MA35624A patent/MA34578B1/fr unknown
- 2011-08-19 WO PCT/EP2011/064260 patent/WO2012022795A1/de not_active Ceased
- 2011-08-19 AU AU2011290727A patent/AU2011290727B2/en not_active Ceased
- 2011-08-19 HR HRP20141172AT patent/HRP20141172T1/hr unknown
- 2011-08-19 ME MEP-2014-118A patent/ME01899B/me unknown
-
2012
- 2012-12-31 IL IL224039A patent/IL224039A/en active IP Right Grant
-
2013
- 2013-01-30 CL CL2013000310A patent/CL2013000310A1/es unknown
- 2013-02-28 CO CO13041062A patent/CO6680689A2/es active IP Right Grant
- 2013-03-15 EC ECSP13012495 patent/ECSP13012495A/es unknown
-
2014
- 2014-11-26 CY CY20141100985T patent/CY1115933T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP13012495A (es) | Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina | |
| DOP2018000257A (es) | Piridinas sustituidas con heteroarilo y métodos de uso | |
| ECSP18090046A (es) | Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| ECSP12012161A (es) | Compuestos en calidad de antagonistas de Bradiquinina-b1 | |
| ECSP12011968A (es) | Nuevos compuestos tricíclicos | |
| CO6341558A2 (es) | Antagonistas del recepptor de nmda para el tratamiento de trastornos neuropsiquiatricos | |
| MX380799B (es) | Ácidos propiónicos 3-sustituidos como inhibidores de la integrina alfa v. | |
| CR20140161A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| ECSP15008851A (es) | Compuestos heteroaromáticos como inhibidores de btk | |
| ECSP10010434A (es) | Inhibidores de hsp90 | |
| MX2016014547A (es) | Compuestos para tratar atrofia muscular espinal. | |
| UY32611A (es) | Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
| CR20140525A (es) | Compuestos de N-alquiltriazol como antagonistas de LPAR | |
| UY36175A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| ECSP10010105A (es) | Antagonistas de cgrp | |
| CO6300955A2 (es) | Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina -3 | |
| NI201000035A (es) | Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3 | |
| ECSP11010786A (es) | 5-alquinil-pirimidinas | |
| AR112787A2 (es) | Compuestos 1,5-difenil-penta-1,4-dien-3-ona | |
| CO6331335A2 (es) | Nuevos compuestos antagonistas de los receptores b1 de bradiquinina | |
| ECSP14002542A (es) | Nuevos 2hindazoles como antagonistas del receptor ep2 | |
| CR20150272A (es) | Derivado de hidantoina | |
| CR20150148A (es) | Azaindolinas | |
| UY31646A1 (es) | Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico | |
| UY31286A1 (es) | Antagonistas de receptores de bradiquinina b1. proceso de preparación y aplicaciones. |